Articles related to DEPRESSION

This report on learnings shows that it is crucial to educate primary healthcare professionals on how to spot people who may commit suicide in their later years (eg, using “The 5 Ds” — Deadly methods, Depression, Disease & Disability, Disconnectness, and Development) and how to adopt prevention measures.

SI, sadness, and anxiety symptoms could all be effectively treated with ketamine. The high rates of response and remission in population samples of TRD were comparable to those for interventional therapies. Racemic ketamine infusion as the main treatment for SI requires randomized controlled trials and comparative efficacy studies with other therapies.

This cohort study discovered that depression, anxiety, perceived stress, loneliness, and worry about COVID-19 were prospectively associated with a 1.3- to 1.5-fold increased risk of self-reported post-COVID-19 conditions, as well as an increased risk of daily life impairment related to post-COVID-19 conditions.

Sixty-one unmedicated adults — 75% female, mean age of 45 years — with major depressive disorder, body mass index > 25 kg/m2, and plasma high-sensitivity C-reactive protein (hs-CRP) ≥ 3.0 mg/L were randomly assigned to receive EPA 1 g/d, 2 g/d, or 4 g/d or placebo for 12 weeks. The EPA 4 g/d demonstrated a medium effect versus placebo. This dose may alleviate MDD in overweight individuals with elevated inflammatory markers. Further, decline in hs-CRP may be correlated with clinical response.

Dextromethorphan HBr-buproprion HCl has been FDA approved in extended-release tablet form for MDD. The study supporting the approval showed improved MADRS total score at 6 weeks (15.9 points for Auvelity vs 12.1 points for placebo) and a statistically significant difference in the change from baseline in MADRS total score at weeks 1 and 2 between Auvelity (AXSOME) and placebo. “The approval of Auvelity represents a milestone in depression treatment based on its novel oral NMDA antagonist mechanism, its rapid antidepressant efficacy demonstrated in controlled trials, and a relatively favorable safety profile.” Maurizio Fava, MD, Psychiatrist-In-Chief, Massachusetts General Hospital

Paolo Manfredi, chief scientific officer at Relmada Therapeutics, remarked, “This designation further supports the potential of REL-1017 as a paradigm-shifting, novel standalone treatment for MDD, and highlights the significant unmet medical need in a therapeutic area where little has changed over the last several decades: available treatments remain inadequate for the majority of patients with MDD.”